Acute kidney injury (AKI) usually is defined as a decline in glomerular filtration rate over hours to days that can occur either in a person with previously normal kidney function, or in the setting of pre-existing chronic kidney disease. The incidence of AKI has increased steadily in recent years, and this increase is associated strongly with advancing age in the population because epidemiologic data indicate that AKI is much more common in the elderly. In the aging population there is heightened susceptibility to drug toxicity, partially owing to altered drug pharmacokinetics and pharmacodynamics. Furthermore, the elderly consume twice as many medications overall, including nephrotoxic agents, compared with younger patients. The vasodilatory increase in the renal plasma flow and glomerular filtration rate that constitutes renal functional reserve is reduced markedly in healthy elderly individuals, compromising renal adaptation after acute ischemia, and heightening susceptibility to AKI. Age-related alterations in renal tubular function also may heighten susceptibility to AKI because renal sodium conservation in response to dietary sodium restriction is attenuated in the elderly. A recently published study showed that elderly subjects with AKI, particularly those with chronic kidney disease, are more likely to develop end-stage renal disease. The increasing prevalence and extended clinical consequences of AKI in the elderly are of great concern from a clinical and public health perspective.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.semnephrol.2009.07.008 | DOI Listing |
Curr Cardiol Rev
January 2025
Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, 342005, India.
Cardiovascular-kidney-metabolic (CKM) syndrome is the association between obesity, diabetes, CKD (chronic kidney disease), and cardiovascular disease. GDF-15 mainly acts through the GFRAL (Glial cell line-derived neurotrophic factor Family Receptor Alpha-Like) receptor. GDF-15 and GDFRAL complex act mainly through RET co-receptors, further activating Ras and phosphatidylinositol-3-kinase (PI3K)/Akt pathways through downstream signaling.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Sydney Medical School, Faculty of Medicine & Health, University of Sydney, Sydney, Australia.
Aim: SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age.
Methods: Pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years).
Crit Care Resusc
December 2024
Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia.
Background: Severe intensive care unit-acquired hypernatraemia (ICU-AH) is a serious complication of critical illness. However, there is no detailed information on how this condition develops.
Objectives: The objective of this study was to study the prevalence, risk factors, trajectory, management, and outcome of severe ICU-AH (≥155 mmol·L).
Crit Care Resusc
December 2024
Paediatric Intensive Care Unit, Royal Children's Hospital, Melbourne, VIC, Australia.
Objective: Frusemide is a common diuretic administered to critically ill children intravenously, by either continuous infusion (CI) or intermittent bolus (IB). We aim to describe the characteristics of children who receive intravenous frusemide, patterns of use, and incidence of acute kidney injury (AKI), and to investigate factors associated with commencing CI.
Design: Retrospective observational study.
Objective: There is uncertainty about whether early infusion of intravenous amino acids confers clinical benefits in critically ill patients. In this study, we aimed to test the hypothesis that intravenous amino acids could improve 90-day mortality in critically ill patients with normal kidney function.
Design: This is a multicentre, open-label, randomised, parallel-controlled trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!